Diet & Nutrition
Eicosapentaenoic acid supplementation benefits chronic hepatitis C patients
Published in Hepatitis Weekly, February 20th, 2006
"EPA has been shown to exert anti-inflammatory actions. To evaluate the effects of EPA on chronic hepatitis C, we administered EPA ethyl ester capsules to patients receiving the combination therapy of interferon alpha-2b and ribavirin," wrote K. Tomioka and colleagues, Okayama Prefectural University.
"EPA (1,800 mg/d) was supplemented in combination with vitamin E (300 mg/d) and C (600 mg/d) to 5 chronic hepatitis C patients (EPA group). Five patients were administered vitamin E and C but not EPA (control group). Blood...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Hepatitis Weekly
Source: Hepatitis Weekly (2006-02-20)
More Articles from Hepatitis Weekly
- Hepatitis B Virus
HBV T cell epitope-based DNA vaccine is therapeutic in transgenic mice - Hepatitis C Virus
CYP2D6 epitope is recognized in autoimmune hepatitis - Hepatitis C Virus
HCV-associated B lymphocyte disorders involve mediated B lymphocyte activation - Hepatitis C Virus
T cell responses differ between chronic HCV infection and HIV/HCV co-infection - Antibacterial Agents
Maker cites Retroscreen Virology study that shows hand sanitizer effective against bird flu - Antiviral Therapy
Antiretroviral therapy response may be altered in HCV antibody-positive HIV-infected patients - More from this issue of Hepatitis Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
